Acurx Pharmaceuticals, Inc. Common Stock (ACXP) is a publicly traded Healthcare sector company. As of May 21, 2026, ACXP trades at $1.89 with a market cap of $7.74M and a P/E ratio of -0.35. ACXP moved +0.00% today. Year to date, ACXP is -33.92%; over the trailing twelve months it is -77.18%. Its 52-week range spans $1.33 to $44.00. Analyst consensus is strong buy with an average price target of $17.00. Rallies surfaces ACXP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Acurx’s DNA pol IIIC Inhibitors Achieve MRSA Reduction and Preserve Gut Diversity: Acurx Pharmaceuticals’ DNA pol IIIC inhibitors maintained Bacteroidota-dominant gut communities and prevented Proteobacteria expansion while achieving therapeutic plasma levels and reducing MRSA tissue burden in neutropenic mice. Preclinical candidates are FDA QIDP and Fast-Track eligible and target CDC Serious Threat Gram-positive infections.
| Metric | Value |
|---|---|
| Price | $1.89 |
| Market Cap | $7.74M |
| P/E Ratio | -0.35 |
| EPS | $-5.32 |
| Dividend Yield | 0.00% |
| 52-Week High | $44.00 |
| 52-Week Low | $1.33 |
| Volume | 77 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-7.97M |
| Gross Margin | 0.00% |
3 analysts cover ACXP: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.00.